FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Peter Langguth

Research Profile

Anatomy

Chemicals & Drugs

Concepts & Ideas

Physiology

Phenomena

Procedures

Living Beings

Rats

Co-author Network

Publications

TOP 3
Rodrigo Cristofoletti; Bertil Abrahamsson; D W Groot; Sabine Kopp; Peter Langguth; Anita Nair; James E. Polli; Vinod P Shah; Jennifer B Dressman
Biowaiver monographs for immediate release solid oral dosage forms: efavirenz.
Peter Langguth; Patrick Marroum
Relationships between in vitro drug dissolution and in vivo response.
Yasuhiro Tsume; Alfredo Garcia-Arieta; Peter Langguth; Gordon L Amidon
In silico prediction of drug dissolution and absorption with variation in intestinal pH for BCS class II weak acid drugs: ibuprofen and ketoprofen.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Peter Langguth (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Rodrigo Cristofoletti; Bertil Abrahamsson; D W Groot; Sabine Kopp; Peter Langguth; Anita Nair; James E. Polli; Vinod P Shah; Jennifer B Dressman
Biowaiver monographs for immediate release solid oral dosage forms: efavirenz.
Journal of pharmaceutical sciences 2013;102(2):318-29.
2012: Peter Langguth; Patrick Marroum
Relationships between in vitro drug dissolution and in vivo response.
Biopharmaceutics & drug disposition 2012;33(7):347-8.
2012: Yasuhiro Tsume; Alfredo Garcia-Arieta; Peter Langguth; Gordon L Amidon
In silico prediction of drug dissolution and absorption with variation in intestinal pH for BCS class II weak acid drugs: ibuprofen and ketoprofen.
Biopharmaceutics & drug disposition 2012;33(7):366-77.
2012: Igor E Shohin; Bertil Abrahamsson; Dirk M Barends; D W Groot; Sabine Kopp; Julia I Kulinich; Peter Langguth; James E. Polli; Galina V Ramenskaya; Vinod P Shah; Jennifer B Dressman
Biowaiver monographs for immediate-release solid oral dosage forms: ketoprofen.
Journal of pharmaceutical sciences 2012;101(10):3593-603.
2012: Asma Radwan; Gordon L Amidon; Peter Langguth
Mechanistic investigation of food effect on disintegration and dissolution of BCS class III compound solid formulations: the importance of viscosity.
Biopharmaceutics & drug disposition 2012;33(7):403-16.
2012: Jennifer B Dressman; D W Groot; Sabine Kopp; Peter Langguth; Anita Nair; James E. Polli; Vinod P Shah; Bertil Abrahamsson; Dirk M Barends; Markus Zimmer
Biowaiver monograph for immediate-release solid oral dosage forms: acetylsalicylic acid.
Journal of pharmaceutical sciences 2012;101(8):2653-67.
2012: Lukas Mühlfeld; Heribert Häusler; Peter Langguth; Hansjörg Hagels
Influence of blister package design on usability among older adults.
International journal of clinical pharmacy 2012;34(4):553-60.
2012: Markus R Jahn; Ute Kolb; Thomas Nawroth; Uwe Wolfrum; Sören Fütterer; Peter Langguth
Iron oxide/hydroxide nanoparticles with negatively charged shells show increased uptake in Caco-2 cells.
Molecular pharmaceutics 2012;9(6):1628-37.
2012: Karsten Gogoll; Markus Radsak; Hansjörg Schild; Pamela Stein; Hai Wei; Peter Langguth
Comparative transcutaneous immunization with imiquimod-containing ointments and potential of in vitro methods to predict effects.
Biopharmaceutics & drug disposition 2012;33(4):218-28.
2012: Karl Buch; Thomas Nawroth; Tanja Peters; Markus Sänger; Heinz Schmidberger; Peter Langguth
Determination of cell survival after irradiation via clonogenic assay versus multiple MTT Assay--a comparative study.
Radiation oncology (London, England) 2012;7():1.
2012: A Hartung; M Knoell; U Schmidt; Peter Langguth
Relevance of air-to-liquid mass ratio effect on final granule properties of an Enalapril maleate formulation.
Drug development and industrial pharmacy 2012;38(1):12-8.
2011: Thomas Nawroth; Karl Buch; Philipp Buch; Peter Langguth; Ralf Schweins
Liposome formation from bile salt-lipid micelles in the digestion and drug delivery model FaSSIF(mod) estimated by combined time-resolved neutron and dynamic light scattering.
Molecular pharmaceutics 2011;8(6):2162-72.
2011: Markus Richard Jahn; Ute Kolb; Thomas Nawroth; Ibrahim Shukoor; Wolfgang Tremel; Uwe Wolfrum; Peter Langguth
Hemin-coupled iron(III)-hydroxide nanoparticles show increased uptake in Caco-2 cells.
The Journal of pharmacy and pharmacology 2011;63(12):1522-30.
2011: Philipp Buch; Carolin Meyer; Peter Langguth
Improvement of the wettability and dissolution of fenofibrate compacts by plasma treatment.
International journal of pharmaceutics 2011;416(1):49-54.
2011: Tobias Schmitz; Christian Schütz; Peter Sharpe; Markus Ziegner; Niels Bassler; Matthias Blaickner; Catrin Grunewald; Michael H Holzscheiter; Jens V Kratz; Peter Langguth; Gerd Otto; Hugo Palmans; Gabriele Hampel
Dose determination using alanine detectors in a mixed neutron and gamma field for boron neutron capture therapy of liver malignancies.
Acta oncologica (Stockholm, Sweden) 2011;50(6):817-22.
2011: Markus R Jahn; Ute Kolb; Hans B Andreasen; Klaus Bock; Sören Fütterer; Wolfgang Hofmeister; Morten Meldal; Manuel Muñoz; Thomas Nawroth; Volker Schünemann; Peter Langguth
A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications.
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft für Pharmazeutische Verfahrenstechnik e.V 2011;78(3):480-91.
2011: Andrea Hartung; Marcus Knoell; Uwe Schmidt; Peter Langguth
Role of continuous moisture profile monitoring by inline NIR spectroscopy during fluid bed granulation of an Enalapril formulation.
Drug development and industrial pharmacy 2011;37(3):274-80.
2011: Boris Obermeier; Peter Langguth; Holger Frey
Partially quarternized amino functional poly(methacrylate) terpolymers: versatile drug permeability modifiers.
Biomacromolecules 2011;12(2):425-31.
2011: Pamela Stein; Ari Waisman; Michael Weber; Hansjörg Schild; Beate Schmid; Edgar Schmitt; Peter Langguth; Hans-Christian Probst; Steve Prüfer; Markus P Radsak
Regulatory T cells and IL-10 independently counterregulate cytotoxic T lymphocyte responses induced by transcutaneous immunization.
PloS one 2011;6(11):e27911.
2011: Thomas Efferth; Peter Langguth
Transport processes of radiopharmaceuticals and -modulators.
Radiation oncology (London, England) 2011;6():59.
2011: P Buch; P Holm; J Q Thomassen; D Scherer; M Kataoka; S Yamashita; Peter Langguth
IVIVR in oral absorption for fenofibrate immediate release tablets using dissolution and dissolution permeation methods.
Die Pharmazie 2011;66(1):11-6.
2011: Pamela Stein; Gerd Rechtsteiner; Tobias Warger; Tobias Bopp; Thorsten Fuhr; Steve Prüfer; Hans-Christian Probst; Michael Stassen; Peter Langguth; Hansjörg Schild; Markus P Radsak
UV exposure boosts transcutaneous immunization and improves tumor immunity: cytotoxic T-cell priming through the skin.
The Journal of investigative dermatology 2011;131(1):211-9.
2010: Lukas Mühlfeld; Peter Langguth; Heribert Häusler; Hansjörg Hagels
Comparison of quantitative analysis techniques for the determination of heat seal lacquer layers on aluminum blister foils.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2010;41(5):700-6.
2010: P Buch; P Holm; J Q Thomassen; D Scherer; M Kataoka; S Yamashita; Peter Langguth
IVIVR in oral absorption for fenofibrate immediate release tablets using dissolution and dissolution permeation methods.
Die Pharmazie 2010;65(10):723-8.
2010: Philipp Buch; Per Holm; Jesper Qvist Thomassen; Dieter Scherer; Robert Branscheid; Ute Kolb; Peter Langguth
IVIVC for fenofibrate immediate release tablets using solubility and permeability as in vitro predictors for pharmacokinetics.
Journal of pharmaceutical sciences 2010;99(10):4427-36.
2010: Eva Hühn; Hans-Georg Buchholz; Gamal Shazly; Stephan Maus; Oliver Thews; Nicole Bausbacher; Frank Rösch; Mathias Schreckenberger; Peter Langguth
Predicting the in vivo release from a liposomal formulation by IVIVC and non-invasive positron emission tomography imaging.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2010;41(1):71-7.
2010: Anna Maria Hofmann; Frederik Wurm; Eva Hühn; Thomas Nawroth; Peter Langguth; Holger Frey
Hyperbranched polyglycerol-based lipids via oxyanionic polymerization: toward multifunctional stealth liposomes.
Biomacromolecules 2010;11(3):568-74.
2009: Rainer Cermak; Silvia Wein; Siegfried Wolffram; Peter Langguth
Effects of the flavonol quercetin on the bioavailability of simvastatin in pigs.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2009;38(5):519-24.
2009: S Grube; Peter Langguth; H E Junginger; S Kopp; K K Midha; V P Shah; S Stavchansky; J B Dressman; D M Barends
Biowaiver monographs for immediate release solid oral dosage forms: quinidine sulfate.
Journal of pharmaceutical sciences 2009;98(7):2238-51.
2009: Karl Buch; Manfred Penning; Eva Wächtersbach; Michael Maskos; Peter Langguth
Investigation of various shellac grades: additional analysis for identity.
Drug development and industrial pharmacy 2009;35(6):694-703.
2009: Philipp Buch; Peter Langguth; Makoto Kataoka; Shinji Yamashita
IVIVC in oral absorption for fenofibrate immediate release tablets using a dissolution/permeation system.
Journal of pharmaceutical sciences 2009;98(6):2001-9.
2008: T Lenhardt; G Vergnault; P Grenier; D Scherer; Peter Langguth
Evaluation of nanosuspensions for absorption enhancement of poorly soluble drugs: in vitro transport studies across intestinal epithelial monolayers.
The AAPS journal 2008;10(3):435-8.
2008: N Ceren Alemdaroglu; Ulrich Dietz; Siegfried Wolffram; Hilde Spahn-Langguth; Peter Langguth
Influence of green and black tea on folic acid pharmacokinetics in healthy volunteers: potential risk of diminished folic acid bioavailability.
Biopharmaceutics & drug disposition 2008;29(6):335-48.
2008: Marija Tubic-Grozdanis; John M Hilfinger; Gordon L Amidon; Jae Seung Kim; Paul Kijek; Petra Staubach; Peter Langguth
Pharmacokinetics of the CYP 3A substrate simvastatin following administration of delayed versus immediate release oral dosage forms.
Pharmaceutical research 2008;25(7):1591-600.
2008: Stefan Grube; Uwe Wolfrum; Peter Langguth
Characterization of the epithelial permeation enhancing effect of basic butylated methacrylate copolymer--in vitro studies.
Biomacromolecules 2008;9(5):1398-405.
2008: Mohammed Ibrahim Shukoor; Filipe Natalio; Nadine Metz; Natalie Glube; Muhammad Nawaz Tahir; Helen Annal Therese; Vadim Ksenofontov; Patrick Theato; Peter Langguth; Jean-Paul Boissel; Heinz C Schröder; Werner E G Müller; Wolfgang Tremel
dsRNA-functionalized multifunctional gamma-Fe2O3 nanocrystals: a tool for targeting cell surface receptors.
Angewandte Chemie (International ed. in English) 2008;47(25):4748-52.
2008: Marija Tubic-Grozdanis; Michael B Bolger; Peter Langguth
Application of gastrointestinal simulation for extensions for biowaivers of highly permeable compounds.
The AAPS journal 2008;10(1):213-26.
2008: Natalie Glube; Peter Langguth
Caki-1 cells as a model system for the interaction of renally secreted drugs with OCT3.
Nephron. Physiology 2008;108(2):p18-28.
2007: A Hanafy; Hilde Spahn-Langguth; G Vergnault; P Grenier; M Tubic Grozdanis; T Lenhardt; Peter Langguth
Pharmacokinetic evaluation of oral fenofibrate nanosuspensions and SLN in comparison to conventional suspensions of micronized drug.
Advanced drug delivery reviews 2007;59(6):419-26.
2007: Markus R Jahn; Yahya Mrestani; Peter Langguth; Reinhard H H Neubert
CE characterization of potential toxic labile iron in colloidal parenteral iron formulations using off-capillary and on-capillary complexation with EDTA.
Electrophoresis 2007;28(14):2424-9.
2007: Natalie Glube; Andreas Giessl; Uwe Wolfrum; Peter Langguth
Caki-1 cells represent an in vitro model system for studying the human proximal tubule epithelium.
Nephron. Experimental nephrology 2007;107(2):e47-56.
2007: Bianca Beilmann; René Kubiak; Peter Grab; Heribert Häusler; Peter Langguth
Effect of interactive ternary mixtures on dispersion characteristics of ipratropium bromide in dry powder inhaler formulations.
AAPS PharmSciTech 2007;8(2):Article 31.
2007: Natalie Glube; Ellen I Closs; Peter Langguth
OCTN2-mediated carnitine uptake in a newly discovered human proximal tubule cell line (Caki-1).
Molecular pharmaceutics 2007;4(1):160-8.
2007: N Ceren Alemdaroglu; Siegfried Wolffram; Jean-Paul Boissel; Ellen I Closs; Hilde Spahn-Langguth; Peter Langguth
Inhibition of folic acid uptake by catechins and tea extracts in Caco-2 cells.
Planta medica 2007;73(1):27-32.
2006: Monika Ofer; Peter Langguth; Hilde Spahn-Langguth
Bidirectional membrane transport: simulations of transport inhibition in uptake studies explain data obtained with flavonoids.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2006;29(3-4):251-8.
2006: Marija Tubic; Daniel Wagner; Hilde Spahn-Langguth; Christine Weiler; Roland Wanitschke; Wulf O Böcher; Peter Langguth
Effects of controlled-release on the pharmacokinetics and absorption characteristics of a compound undergoing intestinal efflux in humans.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2006;29(3-4):231-9.
2006: Marija Tubic; Daniel Wagner; Hilde Spahn-Langguth; Michael B Bolger; Peter Langguth
In silico modeling of non-linear drug absorption for the P-gp substrate talinolol and of consequences for the resulting pharmacodynamic effect.
Pharmaceutical research 2006;23(8):1712-20.
2006: Ulrich Schmitt; A Abou El-Ela; L J Guo; Hristos Glavinas; Peter Krajcsi; J M Baron; C Tillmann; Christoph Hiemke; Peter Langguth; Sebastian Härtter
Cyclosporine A (CsA) affects the pharmacodynamics and pharmacokinetics of the atypical antipsychotic amisulpride probably via inhibition of P-glycoprotein (P-gp).
Journal of neural transmission (Vienna, Austria : 1996) 2006;113(7):787-801.
2006: Bianca Beilmann; Peter Langguth; Heribert Häusler; Peter Grass
High-performance liquid chromatography of lactose with evaporative light scattering detection, applied to determine fine particle dose of carrier in dry powder inhalation products.
Journal of chromatography. A 2006;1107(1-2):204-7.
2005: Monika Ofer; Siegfried Wolffram; Annette Koggel; Hilde Spahn-Langguth; Peter Langguth
Modulation of drug transport by selected flavonoids: Involvement of P-gp and OCT?
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2005;25(2-3):263-71.
2005: Peter Langguth; A Hanafy; D Frenzel; P Grenier; A Nhamias; T Ohlig; G Vergnault; Hilde Spahn-Langguth
Nanosuspension formulations for low-soluble drugs: pharmacokinetic evaluation using spironolactone as model compound.
Drug development and industrial pharmacy 2005;31(3):319-29.
2005: Constanze Hilgendorf; Hilde Spahn-Langguth; Magdalena Rhedin; Carl-Gunnar Regårdh; Björn Löwenadler; Peter Langguth
Selective downregulation of the MDR1 gene product in Caco-2 cells by stable transfection to prove its relevance in secretory drug transport.
Molecular pharmaceutics 2005;2(1):64-73.
2004: Amal Abou El Ela; Sebastian Härtter; Ulrich Schmitt; Christoph Hiemke; Hilde Spahn-Langguth; Peter Langguth
Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates.
The Journal of pharmacy and pharmacology 2004;56(8):967-75.
2004: T Mau; V Hartmann; J Burmeister; Peter Langguth; Heribert Häusler
Development of a sterilizing in-place application for a production machine using Vaporized Hydrogen Peroxide.
PDA journal of pharmaceutical science and technology / PDA 2004;58(3):130-46.
2003: Katharina Brodka-Pfeiffer; Heribert Häusler; Peter Grass; Peter Langguth
Conditioning following powder micronization: influence on particle growth of salbutamol sulfate.
Drug development and industrial pharmacy 2003;29(10):1077-84.
2003: Katharina Brodka-Pfeiffer; Peter Langguth; Peter Grass; Heribert Häusler
Influence of mechanical activation on the physical stability of salbutamol sulphate.
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft für Pharmazeutische Verfahrenstechnik e.V 2003;56(3):393-400.
2003: Sebastian Härtter; Sabine Hüwel; Tina Lohmann; Amal Abou El Ela; Peter Langguth; Christoph Hiemke; Hans-Joachim Galla
How does the benzamide antipsychotic amisulpride get into the brain?--An in vitro approach comparing amisulpride with clozapine.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2003;28(11):1916-22.
2003: Daniel Wagner; Natalie Glube; Nicole Berntsen; Wolfgang Tremel; Peter Langguth
Different dissolution media lead to different crystal structures of talinolol with impact on its dissolution and solubility.
Drug development and industrial pharmacy 2003;29(8):891-902.
2003: D Werdenberg; R Joshi; Siegfried Wolffram; H P Merkle; Peter Langguth
Presystemic metabolism and intestinal absorption of antipsoriatic fumaric acid esters.
Biopharmaceutics & drug disposition 2003;24(6):259-73.
2003: Christiane Leisen; Peter Langguth; Bernd Herbert; Cornelia Dressler; Annette Koggel; Hilde Spahn-Langguth
Lipophilicities of baclofen ester prodrugs correlate with affinities to the ATP-dependent efflux pump P-glycoprotein: relevance for their permeation across the blood-brain barrier?
Pharmaceutical research 2003;20(5):772-8.
2002: Peter Pietzonka; Barbara Rothen-Rutishauser; Peter Langguth; Heidi Wunderli-Allenspach; Elke Walter; Hans P Merkle
Transfer of lipophilic markers from PLGA and polystyrene nanoparticles to caco-2 monolayers mimics particle uptake.
Pharmaceutical research 2002;19(5):595-601.
2002: Peter Pietzonka; Elke Walter; Seraina Duda-Johner; Peter Langguth; Hans P Merkle
Compromised integrity of excised porcine intestinal epithelium obtained from the abattoir affects the outcome of in vitro particle uptake studies.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2002;15(1):39-47.
2002: Pascale Anderle; Peter Langguth; Werner Rubas; Hans P Merkle
In vitro assessment of intestinal IGF-I stability.
Journal of pharmaceutical sciences 2002;91(1):290-300.
2001: D Wagner; Hilde Spahn-Langguth; A Hanafy; Annette Koggel; Peter Langguth
Intestinal drug efflux: formulation and food effects.
Advanced drug delivery reviews 2001;50 Suppl 1():S13-31.
2001: A Hanafy; Peter Langguth; Hilde Spahn-Langguth
Pretreatment with potent P-glycoprotein ligands may increase intestinal secretion in rats.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2001;12(4):405-15.
2001: Hilde Spahn-Langguth; Peter Langguth
Grapefruit juice enhances intestinal absorption of the P-glycoprotein substrate talinolol.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2001;12(4):361-7.
2000: A Hilgeroth; Cornelia Dressler; S Neuhoff; Hilde Spahn-Langguth; Peter Langguth
Dimeric 4-aryl-1,4-dihydropyridines as novel HIV-1 protease inhibitors--affinities to intestinal P-glycoprotein.
Die Pharmazie 2000;55(10):784-5.
2000: S Neuhoff; Peter Langguth; Cornelia Dressler; T B Andersson; Carl-Gunnar Regårdh; Hilde Spahn-Langguth
Affinities at the verapamil binding site of MDR1-encoded P-glycoprotein: drugs and analogs, stereoisomers and metabolites.
International journal of clinical pharmacology and therapeutics 2000;38(4):168-79.
2000: Constanze Hilgendorf; Hilde Spahn-Langguth; Carl-Gunnar Regårdh; E Lipka; Gordon L Amidon; Peter Langguth
Caco-2 versus Caco-2/HT29-MTX co-cultured cell lines: permeabilities via diffusion, inside- and outside-directed carrier-mediated transport.
Journal of pharmaceutical sciences 2000;89(1):63-75.
1999: S Döppenschmitt; Hilde Spahn-Langguth; Carl-Gunnar Regårdh; Peter Langguth
Role of P-glycoprotein-mediated secretion in absorptive drug permeability: An approach using passive membrane permeability and affinity to P-glycoprotein.
Journal of pharmaceutical sciences 1999;88(10):1067-72.
1999: S Döppenschmitt; Peter Langguth; Carl-Gunnar Regårdh; T B Andersson; Constanze Hilgendorf; Hilde Spahn-Langguth
Characterization of binding properties to human P-glycoprotein: development of a [3H]verapamil radioligand-binding assay.
The Journal of pharmacology and experimental therapeutics 1999;288(1):348-57.
1998: U Gietz; R Alder; Peter Langguth; T Arvinte; Hans P Merkle
Chemical degradation kinetics of recombinant hirudin (HV1) in aqueous solution: effect of pH.
Pharmaceutical research 1998;15(9):1456-62.
1998: S Döppenschmitt; Hilde Spahn-Langguth; Carl-Gunnar Regårdh; Peter Langguth
Radioligand-binding assay employing P-glycoprotein-overexpressing cells: testing drug affinities to the secretory intestinal multidrug transporter.
Pharmaceutical research 1998;15(7):1001-6.
1998: P Anderle; E Niederer; Werner Rubas; Constanze Hilgendorf; Hilde Spahn-Langguth; Heidi Wunderli-Allenspach; Hans P Merkle; Peter Langguth
P-Glycoprotein (P-gp) mediated efflux in Caco-2 cell monolayers: the influence of culturing conditions and drug exposure on P-gp expression levels.
Journal of pharmaceutical sciences 1998;87(6):757-62.
1998: Hilde Spahn-Langguth; Gül Baktir; A Radschuweit; Alper Okyar; B Terhaag; P Ader; A Hanafy; Peter Langguth
P-glycoprotein transporters and the gastrointestinal tract: evaluation of the potential in vivo relevance of in vitro data employing talinolol as model compound.
International journal of clinical pharmacology and therapeutics 1998;36(1):16-24.
1997: V B Lang; Peter Langguth; C Ottiger; Heidi Wunderli-Allenspach; D Rognan; Barbara Rothen-Rutishauser; J C Perriard; S Lang; J Biber; Hans P Merkle
Structure-permeation relations of met-enkephalin peptide analogues on absorption and secretion mechanisms in Caco-2 monolayers.
Journal of pharmaceutical sciences 1997;86(7):846-53.
1996: S Lang; Peter Langguth; R Oschmann; B Traving; Hans P Merkle
Transport and metabolic pathway of thymocartin (TP4) in excised bovine nasal mucosa.
The Journal of pharmacy and pharmacology 1996;48(11):1190-6.
1996: P Ader; Beat Grenacher; Peter Langguth; Erwin Scharrer; Siegfried Wolffram
Cinnamate uptake by rat small intestine: transport kinetics and transepithelial transfer.
Experimental physiology 1996;81(6):943-55.
1996: U Wetterich; Hilde Spahn-Langguth; Ernst Mutschler; B Terhaag; W Rösch; Peter Langguth
Evidence for intestinal secretion as an additional clearance pathway of talinolol enantiomers: concentration- and dose-dependent absorption in vitro and in vivo.
Pharmaceutical research 1996;13(4):514-22.
1996: J Heizmann; Peter Langguth; A Biber; R Oschmann; Hans P Merkle; Siegfried Wolffram
Enzymatic cleavage of thymopoietin oligopeptides by pancreatic and intestinal brush-border enzymes.
Peptides 1996;17(7):1083-9.
1995: E Lipka; I D Lee; Peter Langguth; Hilde Spahn-Langguth; E Mutschler; Gordon L Amidon
Celiprolol double-peak occurrence and gastric motility: nonlinear mixed effects modeling of bioavailability data obtained in dogs.
Journal of pharmacokinetics and biopharmaceutics 1995;23(3):267-86.
1994: Peter Langguth; K M Lee; Hilde Spahn-Langguth; Gordon L Amidon
Variable gastric emptying and discontinuities in drug absorption profiles: dependence of rates and extent of cimetidine absorption on motility phase and pH.
Biopharmaceutics & drug disposition 1994;15(9):719-46.
1994: Peter Langguth; G Breves; A Stöckli; Hans P Merkle; Siegfried Wolffram
Colonic absorption and bioavailability of the pentapeptide metkephamid in the rat.
Pharmaceutical research 1994;11(11):1640-5.
1994: C Gido; Peter Langguth; Ernst Mutschler
Predictions of in vivo plasma concentrations from in vitro release kinetics: application to doxepin parenteral (i.m.) suspensions in lipophilic vehicles in dogs.
Pharmaceutical research 1994;11(6):800-8.
1994: Peter Langguth; Hans P Merkle; Gordon L Amidon
Oral absorption of peptides: the effect of absorption site and enzyme inhibition on the systemic availability of metkephamid.
Pharmaceutical research 1994;11(4):528-35.
1994: Peter Langguth; V Bohner; J Biber; Hans P Merkle
Metabolism and transport of the pentapeptide metkephamid by brush-border membrane vesicles of rat intestine.
The Journal of pharmacy and pharmacology 1994;46(1):34-40.
1993: H Weber-Grandke; G Hahn; Ernst Mutschler; W Möhrke; Peter Langguth; Hilde Spahn-Langguth
The pharmacokinetics of tranylcypromine enantiomers in healthy subjects after oral administration of racemic drug and the single enantiomers.
British journal of clinical pharmacology 1993;36(4):363-5.
1993: C Gido; Peter Langguth; Jörg Kreuter; G Winter; H Woog; Ernst Mutschler
Conventional versus novel conditions for the in vitro dissolution testing of parenteral slow release formulations: application to doxepin parenteral dosage forms.
Die Pharmazie 1993;48(10):764-9.
1992: Hilde Spahn-Langguth; G Hahn; Ernst Mutschler; W Möhrke; Peter Langguth
Enantiospecific high-performance liquid chromatographic assay with fluorescence detection for the monoamine oxidase inhibitor tranylcypromine and its applicability in pharmacokinetic studies.
Journal of chromatography 1992;584(2):229-37.
1990: H Spahn; Peter Langguth
Chiral amines derived from 2-arylpropionic acids: novel reagents for the liquid chromatographic (LC) fluorescence assay of optically active carboxylic acid xenobiotics.
Pharmaceutical research 1990;7(12):1262-8.
1990: H Spahn; W Henke; Peter Langguth; J Schloos; Ernst Mutschler
Measurement of carvedilol enantiomers in human plasma and urine using S-naproxen chloride for chiral derivatization.
Archiv der Pharmazie 1990;323(8):465-9.
1990: Peter Langguth; H Spahn; Hans P Merkle
Fluorescence assay for small peptides and amino acids: high-performance liquid chromatographic determination of selected substrates using activated S-flunoxaprofen as a chiral derivatizing agent.
Journal of chromatography 1990;528(1):55-64.
1987: Peter Langguth; Ernst Mutschler
Lipophilisation of hydrophilic compounds. Consequences on transepidermal and intestinal transport of trospium chloride.
Arzneimittel-Forschung 1987;37(12):1362-6.
1987: H Spahn; Peter Langguth; D Krauss; W Kirch; E Mutschler
Pharmacokinetics of atenolol and metoprolol administered together with piroxicam.
Archiv der Pharmazie 1987;320(2):103-7.
1986: H Spahn; Peter Langguth; W Kirch; E Mutschler; E E Ohnhaus
Pharmacokinetics of salicylates administered with metoprolol.
Arzneimittel-Forschung 1986;36(11):1697-9.
1986: Peter Langguth; H Spahn; E Mutschler; K Hübner
An approach to reduce the number of skin samples in testing the transdermal permeation of drugs.
The Journal of pharmacy and pharmacology 1986;38(10):726-30.